Modeling of cyclooxygenase-2 and 5-lipooxygenase inhibitory activity of apoptosis-inducing agents potentially useful in prostate cancer chemotherapy: Derivatives of diarylpyrazole

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 2, 2009, Pages 607-615

  Sharma, B K ^a   Pilania, P ^a   Singh, P ^a  

^a S K Government College   (India)

Author keywords

1,5 diarylpyrazole derivatives; CP MLR approach; Dragon descriptors; QSAR

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LIPOXYGENASE INHIBITOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CALCULATION; DRUG STRUCTURE; ENZYME INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LINEAR MODELS; LIPOXYGENASE INHIBITORS; MALE; MODELS, CHEMICAL; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68049114614     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802318878     Document Type: Article

References (43)

1. Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000;17:109-157.
2. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002;59:799-807.
3. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: A new class of anticancer agents? Lancet Oncol 2003;4:605-615.
4. Haller DG. COX-2 inhibitors in oncology. Semin Oncol 2003; 30:2-8.
5. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 2001;20:195-206.
6. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.
7. Madaan S, Abel PD, Chudhary KS, Heyritt R, Stott MA, Stamp GW, Lalani EN. Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int 2000;86: 736-741.
8. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:125-135.
9. Sabichi AL, Lippman SM. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res 2003;37:163-178.
10. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-4637.
11. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-6312.
12. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 2002;62:2721-2727.
13. His LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signalling in prostate. Alteration in peroxisome proliferators-activated receptor gamma. J Biol Chem 2002;277:40549-40556.
14. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, DuBois RN. (15S)-hydroxyeicosatetraenoic acid activates peroxisome proliferatoractivated receptor g and inhibits proliferation in PC 3 prostate carcinoma cells. Cancer Res 2001;61:497-503.
15. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC 3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001;22:1765-1773.
16. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, Ou D, Harris JE. 5-lipoxygenase inhibitors reduce PC 3 cell proliferation and initiate non-necrotic cell death. Prostate 1998;37:161-173.
17. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825.
18. Song X, Lin HP, Johnson A, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase- 2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-591.
19. Zhu J, Song X, Lin HP, Young DC, Yan S,Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-1757.
20. Marx J. Cancer research. Anti-inflammatories inhibit cancer growths. But how? Science 2001;291:581-582.
21. Srinath P, Rao PN, Knaus EE, Suresh MR. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res 2003;23:3923-3928.
22. Gugliucci A, Ranzato L, Scorrano L, Colonna R, Petronilli V, Cusan C, Prato M, Mancini M, Pagano F, Bernardi P. Mitochondria are direct targets of the lipoxygenase inhibitor MK 886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J Biol Chem 2002;277: 31789-31795.
23. Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F, Henichart JH. New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J Med Chem 2004;47:6195-6206.
24. Desiraju GR, Gopalakrishnan B, Jetti RKR, Raveendra D, Sarma JARP, Subramanya HS. Three-dimensional quantitative structural activity relationship (3D-QSAR) studies of some 1,5-darylpyrazole analog based design of selective cyclooxygenase- 2 inhibitors. Molecules 2000;5:945-955.
25. Liu H, Huang X, Shen J, Luo X, Li M, Xiong B, Chen G, Shen J, Yang Y, Jiang H, Chen K. Inhobitory mode of 1,5- diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: Molecular docking and 3D QSAR analysis. J Med Chem 2002;45:4816-4827.
26. Singh SK, Saibaba V, Rao KS, Reddy PG,Daga PR, Rajjak SA, Misra P, Rao YK. Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore. Euro J Med Chem 2005;40: 977-990.
27. Prasanna S, Manivannan E, Chaturvedi SC. QSAR analysis of conformationally restricted 1,5-diarylpyrazoles as selective COX-2 inhibitors: Application of connection table representations of ligands. Bioorg Med Chem Lett 2005;15: 2097-2102.
28. Thilagavathi R, Chakraborti AK. Importance of alignment in developing 3D-QSAR models of 1,5-diarylpyrazoles for prediction of COX-2 inhibitory activity. Internet Electron J Mol Des 2005;4:603-612.
29. Revathi S, Gupta AK, Soni LK, Kavitha S, Wagh R, Kaskhedikar SG. Rationalization of physicochemical characters of 1,5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: A QSAR approach. J Pharma Biomed Anal 2006; 42:283-289.
30. Dragon software (version 1.11-2001) by Todeschini R, Consonni V. Milano, Italy.
31. Chemdraw ultra 6.0 and Chem3D ultra, Cambridge Soft Corporation, Cambridge, USA.
32. Prabhakar YS. A combinatorial approach to the variable selection in multiple linear regression: Analysis of Selwood et al data set-A case study. QSAR Comb Sci 2003;22:583-595.
33. Gupta MK, Sagar R, Shaw AK, Prabhakar YS. CP-MLR directed QSAR studies on the antimycobacterial activity of functionalized alkenols-topological descriptors in modeling the activity. Bioorg Med Chem 2005;13:343-351.
34. Prabhakar YS, Rawal RK, Gupta MK, Solomon VR, Katti SB. Topological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-pyridyl- thiazolidin-4-ones. Comb Chem High Thro Screen 2005;8:431-437.
35. Gupta MK, Prabhakar YS. Topological descriptors in modeling the antimalarial activity of 4-(30,50-disubstituted aniline)quinolines. J Chem Inf Model 2006;46:93-102.
36. So S-S, Karplus M. Three-dimensional quantitative structureactivity relationship from molecular similarity matrices and genetic neural networks. 1. Method and validation. J Med Chem 1997;40:4347-4359. (Pubitemid 28042314)
37. Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB. CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4- ones. QSAR Comb Sci 2004;23:234-244.
38. SYSTAT, Version 7.0; SPSS Inc., 444 North Michigan Avenue, Chicago, IL, 60611.
39. Akaike H. Information theory and an extension of the minimum likelihood principle. In: Petrov BN, Csaki F, editors. Second international symposium on information theory. Budapest: Akademiai Kiado; 1973. p 267-281.
40. Akaike H. A new look at the statistical identification model. IEEE Trans Autom Control 1974;AC-19:716-723.
41. Kubinyi H. Variable selection in QSAR studies. I. An evolutionary algorithm. Quant Struct-Act Relat 1994;13: 285-294.
42. Kubinyi H. Variable selection in QSAR studies. II. A highly efficient combination of systematic search and evolution. Quant Struct-Act Relat 1994;13:393-401.
43. Friedman J. In Technical Report No. 102. Laboratory for Computational Statistics, Stanford University: Stanford; 1990.